

Original Articles

EFFECT OF LONG- AND SHORT-TERM MINICONSOLIDATION ON SURVIVAL OF PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA

P. NASSERI, A. GHAVAMZADEH, M. KEYHANI
ELAHI, RA. SHARIFIAN, J. NATEGHI, K. ALIMOGHADAM, M.R.
MORTAZAVIZADEH, M. ABASI, AND M.R. ESHRAGHIAN

*From the Department of Hematology-Oncology,
Tehran University of Medical Sciences,
Tehran, I.R. Iran.*

ABSTRACT

A retrospective study was done on 130 AML patients treated in Shariati and Imam Hospitals in Tehran from 1991 to 1997 to investigate the value of three post-remission methods of treatment.

All patients who were in complete remission (CR) (Group I) had been treated with ARA-C (300 mg/m²/day continuous infusion for 5 days) and Daunorubicine (45 mg/m²/day for 3 days) as induction and early consolidation therapy. Forty patients were treated by additional similar chemotherapy as second consolidation and no further treatment was offered. Fifty patients (Group II) were treated by ARA-C (120 mg/m² subcutaneously for 5 days), Etoposide (120 mg/m² on day one), and Mitoxantrone (12 mg/m² on day one) on each successive month as short-term miniconsolidation. Forty patients (Group III) were treated similarly to Group II until relapse for up to two years as long-term miniconsolidation.

There was no difference in the three groups regarding mean age and other prognostic factors. Treatment related mortality and morbidity were also similar. Median duration of disease-free survival (DFS) was 36 (3.5-68 with 95% CI), 17 (12.5-21.5) and 19 (14.7-23.3) months respectively in these three groups. In a 14-month median observation there was no difference in DFS and overall survival (OS) among the three groups ($p=0.7$).

We concluded that short- or long-term miniconsolidation chemotherapy compared to standard treatment does not improve DFS and OS in AML patients.

MJIRI, Vol. 15, No. 2, 61-66, 2001.

Keywords: Acute Myelogenous Leukemia, Consolidation, Maintenance Treatment.

INTRODUCTION

Remission induction (RI) with ARA-C and Anthracyclines is standard treatment in AML, but post-remission treatment differs widely. Standard RI causes

CR in 70% of AML patients, but with no further treatment, long-term event-free survival is nearly impossible^{11,20,27} Post-remission treatments tend to eradicate detectable residual leukemic cells with molecular biology methods.⁵ Several attempts have been made to improve

Effect of Miniconsolidation on AML Patients

treatment results by altering the duration or kinds of drugs used in the remission induction phase, but few or no benefits have been achieved^{12,16} Over the past 30 years there have generally been three classic ways of AML treatment in the post RI period:

1. Maintenance therapy: This prolonged low-dose chemotherapy treatment has been used to increase the DFS or OS.^{14,17,18}

2. Consolidation therapy: In this way two or more courses of combination chemotherapy, comparable with R1 in intensity, have been offered to patients.^{5,7,26}

3. Intensification therapy: Newer attempts with more attractive results have been obtained mainly by more intensive chemotherapy post RI to eradicate the residue of leukemic cells in the bone marrow.⁶ It seems that more intensive treatment in the post-remission period causes a more prolonged duration of DFS; but intensive chemotherapy usually results in more morbidity and mortality due to drug toxicity.^{1,6,25}

In this study we present the treatment results of higher doses used in conventional maintenance chemotherapy for variable duration after RI and compare this treatment with two courses of consolidation therapy. As the drug doses used in these treatments are more than conventional maintenance therapy but less than classic consolidation therapy, we called this treatment miniconsolidation."

PATIENTS AND METHODS

In a retrospective study all AML patients treated from 1990 to 1997 in Shariati and Imam Hospitals in Tehran were considered. Both medical centers are affiliated with Tehran University of Medical Sciences. The criteria were:

1. Patients whose peripheral and bone marrow studies, reported by a pathologist and hematologist, favored AML according to FAB classification.

2. Patients under 60 years of age.

3. Patients who had not previously received chemotherapy.

4. Patients who had received ARA-C (300 mg/m²/d continuous infusion for 5 days) and Daunorubicine (45 mg/m² for the first 3 days) as induction, and classic criteria of remission have been satisfied by one or two courses of the above-mentioned treatment.

5. Patients with preceding myelodysplasia were excluded.

Complete remission was defined as the presence of normal bone marrow with less than 5% blasts, at least 1,500 granulocytes per cubic millimeter, and 100,000 platelets per cubic millimeter in the peripheral blood.

Therapeutic failure causes were subdivided into three categories: resistant leukemia, death during treatment-induced bone marrow hypoplasia, and death within ten

days following remission induction therapy. All of these cases were omitted from this report.

In this study DFS was measured as the length of time from complete remission criteria satisfaction to relapse or death from any cause other than relapse.

Patients who achieved CR had been treated in three fashions as post-remission treatment.

1. Patients treated in Shariati Hospital received two courses of consolidation chemotherapy of the same dose. This treatment was considered as standard treatment.

2. Some patients had been treated by ARA-C (120 mg/m² subcutaneously for 5 days) and Etoposide (120 mg/m² on day one) with or without Mitoxantrone (12 mg/m² on day one) on each of six successive months after remission induction, and a single course of consolidation therapy with a similar regimen as remission induction. This group was called the short-term miniconsolidation group.

3. The third group was treated by the same regimen as Group II, until relapse or for a maximum of 2 years, as long-term miniconsolidation therapy.

The number of patients evaluated totaled 1,083. There were 40, 50 and 40 patients eligible according to the above-mentioned criteria in each successive group respectively. Adding Mitoxantrone in each course of treatment in Groups II and III depended on the patient's CBC and was included when WBC exceeded 4000/mm³.

Remission induction and two courses of consolidation were given as in-patient treatment to patients in Group I. Patients in Groups II and III received remission induction and a single course of consolidation.

Patients in Group I were followed monthly without further treatment. This follow up included physical examination and peripheral blood smear checks every month. And in cases of suspicious relapse immediate bone marrow exam was carried out. OS and DFS distribution were estimated by the Kaplan-Meier method and tested for equality by log rank test. Risk factor frequencies in each group were compared by Chi-square test. The mean age, duration of admission, and expenses were compared by t-test in these groups.

RESULTS

Patients' characteristics are summarized in Table I. It is evident in Table I that there is no significant difference regarding age, subtypes of AML and remission induction times as prognostic factors in these groups.

Median duration of follow up was 14 months. Median duration of DFS in patients who were under or over 40 years of age were 19 (2.1-35.9, 95% CI) and 21 (13.9-28.1, 95% CI) respectively, which was statistically insignificant ($p=0.13$).

Median duration of DFS in Groups I, II and III were

Table I. Characteristics and prognostic factors in 130 AML patients treated in three post-remission chemotherapy sessions.

Group	Age			Sex		Remission induction time		Subtype		Total
	Mean	Max	Min	Male	Female	One	Two	M1, M2, M3	M4, M5 M6	
Group I	28.9	56	14	20	20	56	4	15	25	40
Group II	29.7	65	12	26	24	41	9	26	24	50
Group III	34	72	13	20	20	35	2	22	18	40
<i>p</i> value	0.3					0.18		0.21		

36 (3.5-68.5, 95% CI), 17 (12.5-21.5, 95% CI) and 19 (14.7-23.3, 95% CI) months respectively, with insignificant difference ($p= 0.7$). A comparison of DFS and OS in these groups is summarized in Table II.

As it is evident, there is no statistical difference between DFS and OS in these three groups. The probability of remaining disease-free in relation to the type of post-remission therapy was insignificantly different in 98 patients under the age of 40 and the 32 patients who were over 40 years of age; so these two groups were combined for further analysis. Among 130 patients, the likelihood of remaining disease-free after 18 months was 40% in the first group, 31% in the second group, and 39% in the third group with $p= 0.4$ (Fig. 1).

The main causes of hospitalization in order of frequency were fever, neutropenia and sepsis in 218 cases, and continuous infusion of drugs in 173 cases.

There was no treatment-related mortality in these three groups, but treatment-related side effects, including hematological toxicities, cardiac toxicities, etc., occurred in all three groups which are summarized in Table III.

Mean cost of drugs used were 169,200 Rials (RIs), 486,750 RIs and 1,292,930 RIs respectively, which was significantly higher in Groups II and III ($p= 0.008$ and $p= 0.0001$). Patients in Groups II and III received more prolonged treatment; therefore all costs, including direct

Table II. Patient outcome with three post-remission therapy sessions.

Group	9-Month disease-free survival	18-Month disease-free survival
Group I	0.61	0.45
Group II	0.64	0.32
Group III	0.75	0.41
<i>p</i> value	0.7	0.4

treatment costs, direct non-treatment costs, and indirect costs, were more in these groups. Direct treatment costs are those for items used by the health sector to provide treatment. Direct non-treatment costs are those for resources used by patients and family to gain access to and participate in treatment such as travel, parking and accommodations near a cancer treatment center. Indirect costs are expenses for lost work time incurred by the patient and family required for treatment. A total of 673 courses of miniconsolidation therapy were administered; hospitalization because of fever and neutropenia was required in 30.5% of courses; and packed cell and platelet transfusions were needed in 31.5% of cases.

Table III. Hospital stay and toxic effects following post-remission chemotherapy in three groups.

Group	No. of patients	Treatment courses analyzed	Treatment courses requiring hospitalization	Mean number of hospitalization days per person	Treatment courses requiring blood product transfusion	Cardiotoxicity
Group I	40	80	80 (100%)	28	64	3
Group II	50	345	143 (41%)	29	96	4
Group III	40	418	168 (100%)	38	118	4

Effect of Miniconsolidation on AML Patients




Fig. 1. Cumulative survival curve.

DISCUSSION

Until the early 1980s most AML treatment protocols consisted of one or two bone marrow aplasia inducing treatment cycles followed, if remission was achieved, by monthly maintenance out-patient treatment designed so as not to induce bone marrow aplasia.^{4,10} Median survival time of patients going into remission (53%) was a little over one year.²³ The fact that maintenance regimens which did not induce marrow aplasia were ineffective in eradicating sufficient tumor cells when there was minimal residual disease caused doubt about the effectiveness of this treatment.²³

We hereby present two kinds of post-remission treatments which cause moderate bone marrow aplasia and are more aggressive than conventional maintenance and less toxic than consolidation therapies, using high dose or intermediate doses of ARA-C. The difference between these two is the duration of therapy. The finding of insignificant difference between these two forms of miniconsolidation therapy confirm that a longer duration of treatment does not prolong the duration of remission. Although miniconsolidation is continued for a long time (maximum 2 years in this study), the great majority of its effectiveness is probably derived from the early months of treatment after complete remission. This can be seen in the survival curve (Fig. 1) that shows a cross-

ing of survival curves in the first months of treatment with slight superiority of Groups II and III. But it is evident that in longer follow-up there is no difference in the survival rate between Group I, II and III. Median duration of DFS shows a more prolonged time in Group I compared with Groups II and III. Although this difference is statistically insignificant, it may be a clue to the existing significant difference in larger series of patients in future follow-up. In a CALGB study, in which patients in complete remission were randomized to 8 months or 3 years of maintenance therapy, there was no difference in long-term event-free survival.

Similarly, when repeated courses of induction therapy were administered over 3 to 5 months after CR, before randomization to maintenance therapy or observation, maintenance therapy conferred no additional benefit.⁵

In a previous trial the ECOG randomized patients to receive or not receive two reduced dose courses (by approximately 1/3) of induction therapy before commencing the maintenance program with a 2-year median duration of follow up. EFS for this miniconsolidation plus maintenance versus maintenance therapy alone was 28% versus 14% at 3 years. An update of the data with a median follow up duration of 8 years shows an EFS of 24% versus 12% due to late relapses, suggesting that this only moderately intensive post-remission therapy may have

an improved long-term outcome.⁵

This study again confirms the role of intensity of post-remission therapy in improving the survival.

Several studies^{1,6} showed the efficacy of high dose Cytosar in post-remission treatment of AML. Several studies also showed the ineffectiveness of using high dose ARA-C or other drugs as part of the RI regimen in remission rate and the rate of OS. So the remission induction regimen has not changed over the past 30 years. We used a moderately myelosuppressive regimen in arm 2 and 3 in our study and we found no difference in survival rate between these two arms. Regarding several studies that showed the benefit of high doses of ARA-C in the post-remission period and our study results, we can conclude that:

1. The most important factor influencing the duration of DFS and overall survival in AML patients is the intensity of post-remission treatment.

2. More prolonged treatment with moderate myelosuppressive effects does not increase the DFS and OS. As these treatments are not cost-effective and have comparable toxicity with short courses of more intensive therapy, we do not recommend using these treatments.

ACKNOWLEDGEMENT

The authors appreciate the critical review of the article by M.M. Lari, M.D., Professor of Medicine, and are grateful for his constructive advice.

REFERENCES

1. Appelbaum FR, Clift A, Buckner CD, et al: Allogeneic bone marrow transplantation in patients with acute non-lymphocytic leukemia after first relapse. *Blood* 61: 949-953, 1983.
2. Bell R, Rohatiner AIS, Slevin ML, et al: Short term treatment for acute myelogenous leukemia. *British Medical Journal* 284: 1221-1224, 1982.
3. Buchner TH, Hiddeman W, et al: Intensified induction and consolidation (AML); two multicenter studies of the German AML Cooperative Group. *Journal of Clinical Oncology* 3: 1583-1589, 1985.
4. Cassileth P, Begg C, Bennett J, et al: High dose cytosine arabinoside and amsacrine consolidation therapy without maintenance therapy in adult acute non-lymphocytic leukemia. *Proceedings of the American Society of Clinical Oncology* 5: 149-154, 1986.
5. Cassileth P, Begg C, Bennett J, et al: A randomized study of the efficacy of consolidation therapy in adult non-lymphocytic leukemia. *Blood* 63: 843-847, 1984.
6. Cassileth P, Lynch E, Hines JD, et al: Varying intensity of post-remission therapy in acute myeloid leukemia. *Blood* 79: 1924-1930, 1992.
7. Champline R, Gajewki J, Nimer S, et al: Post-remission chemotherapy for adults with acute myelogenous leukemia; Improved survival with high-dose cytosine arabinoside and daunorubicine consolidation treatment. *Journal of Clinical Oncology* 8: 1199-1204, 1990.
8. Cline MJ, Golde DW: Acute leukemia: biology and treatment. *Annals of Internal Medicine* 91: 758-763, 1979.
9. Cuttner J, Clidewell OJ, Holland JF: A controlled trial of chemoimmunotherapy in acute myelocytic leukemia (AML). (Abstract) *Proceedings of the American Association of Cancer Research* 333: 158-164, 1978.
10. Embury SH, Elias L, Heller PH, Hood CE, et al: Remission maintenance therapy in acute myelogenous leukemia. *West Journal Medicine* 126: 267, 1977.
11. Gale NP, Cline MH: High remission induction rate in acute myeloid leukemia. *Lancet* 1: L96, 1977.
12. Glucksberg H, Buckner DC: Combination chemotherapy for acute non-lymphoblastic leukemia in adults. *Cancer Chemotherapy Reports* 59: 1131, 1975.
13. Hines JD, Oken MM, Muzza J, et al: High dose cytosine arabinoside and M-AmSA is effective therapy in relapsed acute non-lymphocytic leukemia. *Journal of Clinical Oncology* 2: 545-549, 1984.
14. Keating MJ, Smith TL, McCredick B, et al: A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 patients with acute leukemia. *Cancer* 47: 2779-2788, 1981.
15. Peterson BA, Bloomfield CD: Treatment of acute non-lymphocytic leukemia in elderly patients. A prospective study of intensive chemotherapy. *Cancer* 40: 467, 1977.
16. Powles RL, Russell JA: Maintenance of remission in acute myelogenous leukemia by a mixture of BCC and irradiated leukemia cells. *Lancet* 2: 1107, 1977.
17. Preiler HD: A proposal regarding three post-remission induction therapies in acute non-lymphocytic leukemia. *Medical Oncology and Tumor Pharmacology* 3: 43-44, 1986.
18. Preiler HD, Bjornsson SO, Henderson ES: Treatment of acute non-lymphocytic leukemia; use of anthracycline cytosine arabinoside induction therapy and a comparison for two maintenance regimens. *Blood* 53: 455-464, 1979.
19. Preiler HD, Brecher M, Brownman C, et al: The treatment of acute myelocytic leukemia in patients 30 years of age and younger. *American Journal of Hematology* 13: 189-198, 1982.
20. Rai KR, Holland JF, Clidewell CJ, et al: Treatment of acute myelocytic leukemia; a study of cancer and leukemia Group B. *Blood* 58: 1203-1212, 1981.
21. Rees JKH, Swirsky D, Cray RG, Hayhoe FGJ: Principal results of the Medical Research Council's 8th Acute Myeloid Leukemia Trial. *Lancet* Nov. 29, 2 (8518): 1236-1241, 1986.
22. Rudnick SA, Cadman EC: High dose cytosine arabino-

Effect of Miniconsolidation on AML Patients

- side in refractory acute leukemia. *Cancer* 44: 1189, 1979.
23. Sauter C, Berchtold W, Fopp M, et al: Acute myelogenous leukemia, maintenance chemotherapy after early consolidation treatment does not prolong survival. *Lancet* 1: 379, 1984.
 24. Tallman MS, Applebaum F, Fluornoy N, Thomas ED: Evaluation of intensive consolidation therapy for adults with acute non-lymphocytic leukemia using high-dose cytosine arabinoside with asparaginase and amsacrine with etoposide. *Proceedings of the American Society of Clinical Oncology* 5: 165, 1986.
 25. Thomas ED, Buckner CD, Clift NA, et al: Marrow transplantation for acute non-lymphocytic leukemia in first remission. *New England Journal of Medicine* 301: 597, 1979.
 26. Wolff SN, Marian JM, Stein N, et al: High dose cytosine arabinoside and daunorubicine consolidation therapy for acute non-lymphocytic leukemia in first remission, a pilot study. *Blood* 65: 407-411, 1985.
 27. Yates J, Clidewell O, Wienik P, Cooper MN, et al: Cytosine arabinoside with daunorubicine or acute myelocytic leukemia, a CALCB study. *Blood* 65: 454-462, 1982.